^
    CANCER:

    Gastrointestinal Cancer

    MSI-H/dMMR
    CRC
    nivolumab + ipilimumab
    Sensitive: A1 - Approval
    J Clin Oncol - 1 week
    MSI-H/dMMR
    Gastroesophageal Junction Adenocarcinoma
    FLOT
    Sensitive: C3 – Early Trials
    BMC Cancer - 1 week
    MSI-H/dMMR
    Gastric Cancer
    FLOT
    Sensitive: C3 – Early Trials
    BMC Cancer - 1 week
    PIK3CA H1047R
    HCC
    palbociclib + alpelisib
    Sensitive: D – Preclinical
    Cell Death Dis - 1 week
    PIK3CA H1047R
    HCC
    alpelisib + TAK-228
    Sensitive: D – Preclinical
    Cell Death Dis - 1 week
    PIK3CA E545K
    HCC
    alpelisib
    Sensitive: D – Preclinical
    Cell Death Dis - 1 week
    PIK3CA H1047R
    HCC
    alpelisib
    Resistant: D – Preclinical
    Cell Death Dis - 1 week
    MSI-H/dMMR
    Gastric Cancer
    dostarlimab
    Sensitive: A2 - Guideline
    NCCN - 2 weeks
    HER-2 positive
    Gastric Cancer
    ARX788
    Sensitive: C3 – Early Trials
    Ambrx Press Release - 2 weeks
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    ARX788
    Sensitive: C3 – Early Trials
    Ambrx Press Release - 2 weeks
    KRAS G12C
    CRC
    bevacizumab
    Resistant: C3 – Early Trials
    Frontiers - 2 weeks
    No biomarker
    HCC
    pembrolizumab
    Sensitive: A1 - Approval
    Merck (MSD) Press Release - 3 weeks
    FGFR2 rearrangement
    Cholangiocarcinoma
    TAS 120
    Sensitive: B - Late Trials
    Cancer Discov - 3 weeks
    FGFR2 fusion
    Cholangiocarcinoma
    TAS 120
    Sensitive: B - Late Trials
    Cancer Discov - 3 weeks
    No biomarker
    Biliary Tract Cancer
    fosgemcitabine palabenamide
    Sensitive: B - Late Trials
    NuCana Press Release - 3 weeks
    IDH1 mutation
    Cholangiocarcinoma
    ivosidenib
    Sensitive: A1 - Approval
    JAMA Oncol - 3 weeks
    BRAF V600E
    CRC
    cetuximab + encorafenib
    Sensitive: A1 - Approval
    FDA - 3 weeks
    miR-7-5p overexpression
    CRC
    bevacizumab
    Resistant: C3 – Early Trials
    Dovepress - 3 weeks
    TSPAN6 positive
    CRC
    cetuximab
    Sensitive: C3 – Early Trials
    PNAS - 3 weeks
    miR-143-3p overexpression
    CRC
    bevacizumab
    Sensitive: C3 – Early Trials
    Dovepress - 3 weeks
    miR-10a-5p overexpression
    CRC
    bevacizumab
    Resistant: C3 – Early Trials
    Dovepress - 3 weeks
    HRD
    Pancreatic Cancer
    ABT-888
    Resistant: C4 – Case Studies
    Clin Cancer Res - 3 weeks
    HER-2 positive
    Gastric Cancer
    trastuzumab
    Sensitive: A2 - Guideline
    J Gastrointest Cancer - 4 weeks
    FGFR2 amplification
    Gastric Cancer
    TAS 120
    Sensitive: C2 – Inclusion Criteria
    Cancer Discov - 4 weeks
    FGFR3-TACC3 fusion
    Gastric Cancer
    TAS 120
    Sensitive: C3 – Early Trials
    Cancer Discov - 4 weeks
    FGFR2-POC1B fusion
    Cholangiocarcinoma
    TAS 120
    Sensitive: C4 – Case Studies
    Cancer Discov - 4 weeks
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Cancer
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Gastric Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A1 - Approval
    BRCA2 mutation
    Pancreatic Cancer
    olaparib
    Sensitive: A1 - Approval
    No biomarker
    HCC
    bevacizumab + atezolizumab
    Sensitive: A1 - Approval
    BRCA1 mutation
    Pancreatic Cancer
    olaparib
    Sensitive: A1 - Approval
    FGFR2 rearrangement
    Cholangiocarcinoma
    infigratinib
    Sensitive: A1 - Approval
    FGFR2 fusion
    Cholangiocarcinoma
    infigratinib
    Sensitive: A1 - Approval
    MSI-H/dMMR
    CRC
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    TPF
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    TPF
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    pembrolizumab + trastuzumab
    Sensitive: A1 - Approval
    BRAF V600E
    CRC
    cetuximab + encorafenib + binimetinib
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    capecitabine
    Sensitive: A1 - Approval
    No biomarker
    Rectal Cancer
    FOLFIRI
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    5-fluorouracil + irinotecan
    Sensitive: A1 - Approval
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    CRC
    bevacizumab
    Sensitive: A1 - Approval
    HER-2 Negative + PD-L1 expression
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    trastuzumab
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Cancer
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Rectal Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    Zirabev (bevacizumab biosimilar)
    Resistant: A1 - Approval
    No biomarker
    CRC
    trifluridine/tipiracil
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    trifluridine/tipiracil
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    trifluridine/tipiracil
    Sensitive: A1 - Approval
    No biomarker
    Pancreatic Adenocarcinoma
    gemcitabine + albumin-bound paclitaxel
    Sensitive: A1 - Approval
    No biomarker
    Pancreatic Adenocarcinoma
    5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    ramucirumab
    Sensitive: A1 - Approval
    No biomarker
    HCC
    cabozantinib tablet
    Sensitive: A1 - Approval
    No biomarker
    CRC
    ziv-aflibercept IV
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    capecitabine
    Sensitive: A1 - Approval
    No biomarker
    CRC
    capecitabine
    Sensitive: A1 - Approval
    No biomarker
    Pancreatic Cancer
    erlotinib
    Sensitive: A1 - Approval
    EGFR expression
    CRC
    cetuximab
    Sensitive: A1 - Approval
    KRAS Q61
    CRC
    cetuximab
    Resistant: A1 - Approval
    No biomarker
    CRC
    ramucirumab
    Sensitive: A1 - Approval
    No biomarker
    CRC
    panitumumab
    Sensitive: A1 - Approval
    KRAS A146
    CRC
    cetuximab
    Resistant: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    ramucirumab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Rectal Cancer
    irinotecan
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    irinotecan
    Sensitive: A1 - Approval
    No biomarker
    HCC
    sintilimab + Byvasda (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive: A1 - Approval
    PD-L1 expression
    Esophageal Cancer
    pembrolizumab
    Sensitive: A1 - Approval
    AFP elevation
    HCC
    ramucirumab
    Sensitive: A1 - Approval
    No biomarker
    HCC
    regorafenib
    Sensitive: A1 - Approval
    No biomarker
    HCC
    lenvatinib
    Sensitive: A1 - Approval
    No biomarker
    HCC
    sorafenib
    Sensitive: A1 - Approval
    KRAS G13
    CRC
    cetuximab
    Resistant: A1 - Approval
    KRAS G12
    CRC
    cetuximab
    Resistant: A1 - Approval
    No biomarker
    CRC
    Aybintio (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    MSI-H/dMMR
    CRC
    nivolumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    FGFR2 rearrangement
    Cholangiocarcinoma
    pemigatinib
    Sensitive: A1 - Approval
    FGFR2 fusion
    Cholangiocarcinoma
    pemigatinib
    Sensitive: A1 - Approval
    No biomarker
    CRC
    regorafenib
    Sensitive: A1 - Approval
    KRAS K117
    CRC
    cetuximab
    Resistant: A1 - Approval
    KRAS A59
    CRC
    cetuximab
    Resistant: A1 - Approval
    No biomarker
    HCC
    nivolumab + ipilimumab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    KRAS G12S
    CRC
    panitumumab
    Resistant: A1 - Approval
    NRAS Q61
    CRC
    cetuximab
    Resistant: A1 - Approval
    NRAS Q61
    CRC
    panitumumab
    Resistant: A1 - Approval
    NRAS G13
    CRC
    panitumumab
    Resistant: A1 - Approval
    NRAS G13
    CRC
    cetuximab
    Resistant: A1 - Approval
    NRAS G12
    CRC
    panitumumab
    Resistant: A1 - Approval
    NRAS G12
    CRC
    cetuximab
    Resistant: A1 - Approval
    NRAS A146
    CRC
    cetuximab
    Resistant: A1 - Approval
    NRAS A146
    CRC
    panitumumab
    Resistant: A1 - Approval
    KRAS G13
    CRC
    panitumumab
    Resistant: A1 - Approval
    KRAS G61
    CRC
    panitumumab
    Resistant: A1 - Approval